An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture
概览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- First Affiliated Hospital of Chongqing Medical University
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Differences in Gut and Urinary Microbiome Composition
概览
简要总结
The goal of this observational study is to investigate the systemic pathogenesis and identify potential diagnostic biomarkers in patients with ureteral stricture and healthy volunteers. The main questions it aims to answer are:
What are the systemic differences in the gut microbiome, urine microbiome, and metabolomic profiles (fecal, urinary, and serum) between patients with ureteral stricture and healthy controls? What are the correlations between these microbial/metabolic alterations and clinical phenotypes, such as stricture severity, inflammatory levels, and renal function? Researchers will compare the biological panoramic profiles of patients with ureteral stricture to those of healthy controls to see if specific "microbiome-metabolite-disease" regulatory networks drive the development of the condition.
Participants will:
Provide stool samples for gut microbiome (16S/Metagenomics) and metabolomic analysis.
Provide urine samples for urine microbiome and metabolomic analysis. Provide blood (serum) samples for systemic metabolomic profiling. Undergo clinical assessments, including medical history collection, imaging (e.g., CT/IVP), and laboratory tests (e.g., renal function, inflammatory markers) to evaluate disease severity.
详细描述
Background and Scientific Rationale Ureteral stricture is a major urological challenge that leads to urinary tract obstruction and progressive renal impairment. While its etiology is diverse-ranging from iatrogenic injury to congenital anomalies-the underlying molecular mechanisms, particularly in inflammatory and idiopathic cases, remain poorly understood. Current surgical interventions carry a risk of recurrence, underscoring the urgent need to identify systemic biomarkers and novel therapeutic targets.
The Gut-Kidney Axis and Urinary Microbiome Recent advances have highlighted the "gut-kidney axis," where the gut microbiota and its metabolites modulate distant organ pathology through immune regulation and metabolic signaling. Furthermore, the discovery of a unique urinary microbiome has challenged the traditional view of urinary sterility, suggesting that local dysbiosis may contribute to urological diseases. Metabolites, serving as the functional intermediaries between the microbiome and the host phenotype, provide a critical bridge to understanding these complex interactions.
Integrated Multi-omics Strategy
This study adopts an innovative integrated multi-omics approach to characterize the biological landscape of ureteral stricture across three compartments: the intestine, the urinary tract, and the systemic circulation. By combining high-throughput sequencing of gut and urine microbiomes with mass spectrometry-based metabolomic profiling (fecal, urinary, and serum), we aim to:
Map Systemic Dysbiosis: Identify specific microbial taxa and metabolic signatures that distinguish patients with ureteral stricture from healthy individuals.
Elucidate Regulatory Networks: Construct "microbiome-metabolite-disease" networks to explore how microbial alterations correlate with clinical phenotypes, such as fibrosis markers, inflammatory levels, and renal function indicators.
Identify Functional Pathways: Utilize functional enrichment analysis to pinpoint metabolic pathways (e.g., those related to inflammation or tissue fibrosis) that are modulated by the microbiota.
Clinical Significance The ultimate goal of this research is to provide a systemic biological perspective on the pathogenesis of ureteral stricture. By integrating cross-platform data, we expect to identify high-sensitivity non-invasive biomarkers for early diagnosis and provide a theoretical foundation for future microecology-targeted interventions.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •(Ureteral Stricture Group):
- •Age between 18 and 75 years, regardless of gender. Diagnosis of ureteral stricture confirmed by clinical symptoms and imaging (e.g., CT, IVP, or retrograde pyelography) or ureteroscopy.
- •The patient is scheduled for or undergoing standard clinical evaluation/treatment for ureteral stricture.
- •Willingness to provide stool, urine, and blood samples. Informed consent signed by the participant or their legal representative.
- •Inclusion Criteria (Healthy Control Group):
- •Age- and sex-matched volunteers (18-75 years). No history of ureteral stricture, urinary tract obstruction, or significant renal disease.
- •Physical examination and laboratory tests (renal function, routine urine analysis) are within normal limits.
排除标准
- •(Applicable to Both Groups):
- •Use of antibiotics, probiotics, prebiotics, or antifungal medications within the 4 weeks prior to sample collection.
- •History of chronic gastrointestinal diseases (e.g., Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), or chronic diarrhea).
- •Known malignant tumors of the urinary tract or other systemic malignancies. History of major abdominal or urinary tract surgery within the last 3 months (excluding the current planned procedure for patients).
- •Presence of severe systemic diseases, including uncontrolled diabetes, severe hepatic dysfunction, or end-stage heart failure.
- •Pregnancy or breastfeeding. Any other condition that, in the opinion of the investigator, may interfere with the microbiome or metabolomic analysis.
研究组 & 干预措施
Ureteral Stricture Group
Patients diagnosed with ureteral stricture through clinical symptoms, imaging (e.g., CT, IVP, or retrograde pyelography), or endoscopic evaluation. This cohort includes individuals with iatrogenic, inflammatory, or idiopathic strictures. Intervention of interest: Participants will undergo biological sample collection, including fecal samples for gut microbiome and metabolome analysis, mid-stream urine for urinary microbiome and metabolome analysis, and fasting blood samples for systemic serum metabolomic profiling. Clinical data such as renal function and stricture characteristics will also be recorded.
Healthy Control Group
Age- and sex-matched healthy volunteers with no history of ureteral stricture, urinary tract obstruction, or significant renal diseases. Candidates with recent (within 3 months) use of antibiotics or probiotics, or those with chronic gastrointestinal or metabolic disorders, are excluded. Intervention of interest: This cohort will provide identical biological samples (fecal, urine, and blood) following the same protocols as the patient group to establish a baseline for comparative multi-omics analysis.
结局指标
主要结局
Differences in Gut and Urinary Microbiome Composition
时间窗: Baseline (at the time of sample collection, within 1 week of enrollment)
Comparison of microbial diversity and taxonomic composition between ureteral stricture patients and healthy controls. Metrics include Alpha-diversity (e.g., Shannon Index), Beta-diversity (e.g., PCoA based on Bray-Curtis distance), and relative abundance of specific microbial taxa from Phylum to Genus levels using 16S rRNA or metagenomic sequencing.
Differential Metabolomic Profiles in Fecal, Urinary, and Serum Samples
时间窗: Baseline (at the time of sample collection, within 1 week of enrollment)
Identification of significantly different metabolites between the two groups. Parameters include the concentration and relative intensity of metabolites identified via LC-MS/MS or GC-MS. Significant metabolites will be screened based on Variable Importance in Projection (VIP) \> 1.0 and p-value \< 0.05 from multivariate and univariate statistical analyses.
次要结局
未报告次要终点
研究者
Gang Chen
Gang Chen
First Affiliated Hospital of Chongqing Medical University